Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral, extended release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. It also provides its products for various medical indications comprising glaucoma, cholesterol, muscle spasm, migraine, pain management, cardiovascular, antipsychosis, gastrointestinal, urinary, bronchospasms, respiratory, gallstone, congestive heart failure, thyroid deficiency, central nervous system, and gout. In addition, the company manufactures active pharmaceutical ingredients; and markets its products under the Diamox, Lipitor, Lioresal, Fioricet, Fiorinal, Lanoxin, Prolixin, MiraLAX, Imdur, Levoxyl/Synthroid, Metadate CD, Concerta, Procardia, Prilosec, Ditropan, Protonix, Imitrex, Brethine, Tussionex, and Actigall brands. Further, it sells pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with JSP, Summit Bioscience LLC, HEC Pharm Group, and Pharma Pass II LLC. Lannett Company, Inc. was founded in 1942 and is based in Philadelphia, Pennsylvania.
